Agios Pharmaceuticals Inc. (AGIO) carries a Roarable Rating of D- (Sell) with 35/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
As of 2026-11-03, Agios Pharmaceuticals Inc. (NASDAQ: AGIO) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 35/100 at a spot price of $29.95 (-1.96% 1D, market cap $1.82B). Pillar breakdown: Fundamental Cash Engine 9/20, Institutional 13F & Options Flow 6/20, SEC Balance-Sheet Forensics 14/20, FRED Macro Regime Fit 3/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, AGIO ranks #589 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), AGIO carries a Roarable D- (35/100 RQD), trailing P/E of N/A, gross margin of 88.3%, and ROIC of -33.8%. By comparison, ADRX (ADARx Pharmaceuticals Inc.) holds a D grade (48/100 RQD, P/E N/A, ROIC —, cap $1.82B) and ZBIO (Zenas BioPharma Inc.) posts a D- grade (38/100 RQD, P/E N/A, ROIC -35.0%, cap $1.85B). Among the 5-stock peer group, AGIO leads on earnings multiple (N/A) while AGIO leads on capital efficiency (-33.8% ROIC).
Per AGIO's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001439222), Agios Pharmaceuticals Inc. generated $54.0M in revenue (+48.0% YoY), -$413.0M in net income, and -$377.3M in free cash flow against $1.30B in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
Altman Z-Score 11.84 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 4/9
SEC XBRL FY 2025 (10-K): 0% FCF Margin ($0 FCF) & 88.3% Gross Margin
Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment
While AGIO currently carries a cautious 35/100 (D-) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
Established market leader in Health Care with deep daily trading liquidity.
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($33.67) and Max Pain ($31.45) forces dealer call-delta covering toward $48.30.
Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
Agios Pharmaceuticals Inc. (AGIO) slipped -1.96% to $29.95, trading at 32% of its 52-week range ($22.24 – $46). Stretched risk/reward at current multiples (-34% return on capital) under elevated 10-year interest-rate pressure.
Yahoo! Finance Canada report covering Agios Pharmaceuticals Inc. (AGIO) market action, institutional positioning, and fundamental catalysts.
TradingView report covering Agios Pharmaceuticals Inc. (AGIO) market action, institutional positioning, and fundamental catalysts.
Seeking Alpha report covering Agios Pharmaceuticals Inc. (AGIO) market action, institutional positioning, and fundamental catalysts.
kalkine.ca report covering Agios Pharmaceuticals Inc. (AGIO) market action, institutional positioning, and fundamental catalysts.
Yahoo Finance report covering Agios Pharmaceuticals Inc. (AGIO) market action, institutional positioning, and fundamental catalysts.
Simply Wall St report covering Agios Pharmaceuticals Inc. (AGIO) market action, institutional positioning, and fundamental catalysts.
Stock Titan report covering Agios Pharmaceuticals Inc. (AGIO) market action, institutional positioning, and fundamental catalysts.
Key TakeawaysAgios Pharmaceuticals shares fell [19%] after the FDA moved its mitapivat decision in sickle cell disease to Feb. 1, 2027.
Agios Pharmaceuticals stock fell >15% after the FDA extended the mitapivat sNDA PDUFA date for sickle cell disease to February 2027. I rate AGIO stock as Buy. Read my update.
FDA recently requested additional information to evaluate whether a REMS is necessary for mitapivat in sickle cell diseaseFDA classified Agios’ response to the information request as a major amendment to the mitapivat sN
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +48.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on AGIO today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for AGIO. Explore sector supply chains on /butterfly.
Across 1015 tracked Health Care securities in the Roarable RQD universe, Agios Pharmaceuticals Inc. (AGIO) ranks #589 by composite RQD confidence (35/100, grade D-) and #271 by equity capitalization ($1.82B). Within this direct 5-issuer industry benchmark cohort, AGIO leads on earnings valuation at N/A trailing P/E, while AGIO leads on capital efficiency and profitability with -33.8% ROIC and 88.3% gross margin. GENB currently holds the highest overall quantitative score in the immediate peer group at 52/100 (D+) compared with AGIO at 35/100 (D-).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| AGIO
ACTIVE
Agios Pharmaceuticals Inc. | D- | 35/100 | — | 88.3% | -33.8% | -1.96% | $1.82B | Benchmark Subject |
| ADRX ADARx Pharmaceuticals Inc. | D | 48/100 | — | — | — | -7.29% | $1.82B | /adrx-vs-agio → |
| ZBIO Zenas BioPharma Inc. | D- | 38/100 | — | — | -35.0% | -2.71% | $1.85B | /zbio-vs-agio → |
| GENB Generate Biomedicines Inc. | D+ | 52/100 | — | — | — | -8.64% | $1.86B | /genb-vs-agio → |
| TRAX First Tracks Biotherapeutics Inc. | D | 44/100 | — | — | -35.0% | -0.07% | $1.89B | /trax-vs-agio → |
In its most recent audited fiscal period (FY2025, filed 2025-12-31), Agios Pharmaceuticals Inc. (AGIO) reported GAAP revenue of $54.0M (+48.0% vs. FY2024 revenue of $36.5M , and +101.4% cumulative change since FY2023) , GAAP net income of -$413.0M, operating cash flow of -$373.0M, and free cash flow of -$377.3M (+3.6% YoY). On the balance sheet, AGIO closed FY2025 with $1.30B in total assets against $0 in total debt (Altman Z-Score: 11.84, Piotroski F-Score: 4/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $54.0M | -$413.0M | -$373.0M | -$377.3M | $1.30B | — |
| FY2024 (FY) | 2024-12-31 | $36.5M | $674.0M | -$389.8M | -$391.5M | $1.66B | — |
| FY2023 (FY) | 2023-12-31 | $26.8M | -$352.0M | -$296.1M | -$296.1M | — | — |
As of 2026-11-03, Agios Pharmaceuticals Inc. (NASDAQ: AGIO) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 35/100 at a spot price of $29.95 (-1.96% 1D, market cap $1.82B). Pillar breakdown: Fundamental Cash Engine 9/20, Institutional 13F & Options Flow 6/20, SEC Balance-Sheet Forensics 14/20, FRED Macro Regime Fit 3/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, AGIO ranks #589 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), AGIO carries a Roarable D- (35/100 RQD), trailing P/E of N/A, gross margin of 88.3%, and ROIC of -33.8%. By comparison, ADRX (ADARx Pharmaceuticals Inc.) holds a D grade (48/100 RQD, P/E N/A, ROIC —, cap $1.82B) and ZBIO (Zenas BioPharma Inc.) posts a D- grade (38/100 RQD, P/E N/A, ROIC -35.0%, cap $1.85B). Among the 5-stock peer group, AGIO leads on earnings multiple (N/A) while AGIO leads on capital efficiency (-33.8% ROIC).
Per AGIO's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001439222), Agios Pharmaceuticals Inc. generated $54.0M in revenue (+48.0% YoY), -$413.0M in net income, and -$377.3M in free cash flow against $1.30B in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.
AGIO last traded at $29.95 (-1.96% on volume of 1,912,701 shares), positioning the stock -11.05% below its 50-day simple moving average ($33.67) and -5.70% below its 200-day simple moving average ($31.76). Across its 52-week range of $22.24 to $46.00, AGIO sits at the 32.4% percentile with a 14-day RSI of 42.5 (NEUTRAL RANGE) and an implied next-earnings move of ±11.7% ($26.45 to $33.45).
Agios Pharmaceuticals Inc. (AGIO) earns a live Roarable RQD composite score of 35/100, corresponding to a D- letter grade (Roarable Sell) at a spot price of $29.95 (-1.96% 1D, market capitalization $1.82B).
Agios Pharmaceuticals Inc. Is a NASDAQ-listed issuer in the Health Care sector, operating in the Biotechnology: Pharmaceutical Preparations industry. The market capitalization is $2.2B.
In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Agios Pharmaceuticals Inc. (AGIO) reported $54.0M in annual revenue (up from $36.5M in FY2024, +48.0% YoY) and -$413.0M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($26.8M revenue, -$352.0M net income) through FY2025, AGIO scaled operating cash flow to -$373.0M and free cash flow to -$377.3M, backed by $1.30B in total assets against $0 in total debt.
The source data therefore does not establish any upstream or downstream dependencies, sector correlations, or 2nd-order bottlenecks.
Real-time company headlines, analyst actions, and sector developments for Agios Pharmaceuticals Inc. (AGIO) • Click "Debate This Headline" to argue it in the Roar Pit below
Yahoo! Finance Canada report covering Agios Pharmaceuticals Inc. (AGIO) market action, institutional positioning, and fundamental catalysts.
TradingView report covering Agios Pharmaceuticals Inc. (AGIO) market action, institutional positioning, and fundamental catalysts.
Seeking Alpha report covering Agios Pharmaceuticals Inc. (AGIO) market action, institutional positioning, and fundamental catalysts.
kalkine.ca report covering Agios Pharmaceuticals Inc. (AGIO) market action, institutional positioning, and fundamental catalysts.
Yahoo Finance report covering Agios Pharmaceuticals Inc. (AGIO) market action, institutional positioning, and fundamental catalysts.
Simply Wall St report covering Agios Pharmaceuticals Inc. (AGIO) market action, institutional positioning, and fundamental catalysts.
Stock Titan report covering Agios Pharmaceuticals Inc. (AGIO) market action, institutional positioning, and fundamental catalysts.
Key TakeawaysAgios Pharmaceuticals shares fell [19%] after the FDA moved its mitapivat decision in sickle cell disease to Feb. 1, 2027.
Don't sleep on AGIO's setup in Health Care. The Forensic Balance Sheet pillar scores 14 of 20 with an Altman Z of 11.84, indicating financial resilience despite cash burn.. Beta of 1.0 means it moves fast when momentum turns, and the 5-pillar RQD gauge (35/100) backs up the fundamental quality.
@FadeTheHype Shorting a 6/20 institutional whale-flow stock at $30.55 is dangerous when funds are rotating into Health Care.
Fading this rally in AGIO at $30.55. Free cash flow was -$377.3M in FY 2025 with an FCF yield of -16.97% and an ROIC of -33.8%, while the Insider Conviction pillar scores only 3 of 20.. With a beta of 1.0 and the stock sitting at $30.55 (52-wk range $22.24–$46.00), the easy multiple expansion is already priced in.
To protect compute speed and zero-delay Cboe BZX data quality for active members, our current $9.95/month Roarable Pro cohort is 100% full. Join the priority waiting list below and we will notify you the moment the next batch of Pro accounts opens (and lock in your $9.95/mo rate).
Link your personal ChatGPT, Claude Desktop, or Cursor via Roarable's Model Context Protocol (`mcp.roarable.com`) to query all 5,289 stocks, inspect Butterfly supply chains, and trade your `$100K Arena` account.
Interrogate SEC 10-K/10-Q filings on demand and ask custom ticker, valuation, or short-thesis questions directly to any of our 8 specialized AI Quant Analysts.
Command our AI agents to sort and sift 5,289 stocks by custom formulas, follow multi-indicator technical & cash-flow setups, and send you instant Email/SMS breakout & downgrade alerts.
Unlock sub-second Cboe BZX streaming quotes, pre-market/after-hours delta scanners, instant SEC Form 4 insider cluster alerts, and unlimited portfolio stress-testing.
All 8 Roarable Analysts (Mara Quenwick, Gideon Ashmere, Ellis Vennor, Tessa Rookmere, Soren Halewick, Iona Brackenford, Nadia Vellacrest, and Felix Orven) are proprietary AI Quant Analysts and automated algorithmic specialists — not human financial advisors, fiduciaries, or registered broker-dealers. While one-to-many daily stock ratings and briefings are free, custom 1-on-1 Q&A, custom AI sifting/indicator alert agents, and personal ChatGPT/Claude MCP connections consume dedicated per-user compute and require a $9.95/month Roarable Pro membership. All AI outputs are for educational and research purposes only and never constitute individualized investment advice.
Enter your email address below for instant 1-step account activation, daily A–E stock rating alerts, and immediate access to your $100,000.00 Virtual Cash Arena account (100% free — no credit card required).